NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01874353,Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy,https://clinicaltrials.gov/study/NCT01874353,,ACTIVE_NOT_RECRUITING,"A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary peritoneal and / or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum based chemotherapy.",YES,Platinum Sensitive|BRCA Mutated|Relapsed Ovarian Cancer|Following Complete or Partial Response to Platinum Based Chemotherapy,DRUG: Olaparib 300mg tablets|DRUG: Placebo to match olaparib 300mg,"Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1), To determine the efficacy by progression free survival (PFS) (using investigator assessment according to modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)) of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy., Radiologic scans performed at baseline then every ~12 weeks up to 72 weeks, then every ~ 24 weeks thereafter until objective radiological disease progression. Assessed until 19 Sep 2016 DCO (16 Jan 2017 DCO for China Cohort); up to a maximum of 36 months.","Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Overall Survival, To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of overall survival (OS)., Survival assessed every 4 weeks until treatment discontinues, then every 12 weeks. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.|Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time to Earliest Progression by RECIST or Cancer Antigen (CA-125) or Death, To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of time to earliest progression by RECIST or CA-125 or death., CA-125 at baseline then every 4 wks. Radiologic scans at baseline then every ~12 wks up to 72 wks, then every ~ 24 wks until objective radiological disease progression. Assessed until 19Sep2016 DCO (16Jan2017 DCO for China Cohort); up to a max of 36 mths.|Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time From Randomization to Second Progression, To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization up to second progression, Scans at baseline then every 12 wks for 72 wks, then every 24 wks until first progression. Assessments then per local practice every 12 wks until second progression. Assessed until 19Sep2016 DCO (16Jan2017 DCO for China Cohort); up to a max of 36 mths|Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O), To compare the effects of olaparib maintenance monotherapy compared to placebo on Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy. The TOI ranges from 0-100 and a higher score indicates a higher HRQoL., Questionnaires completed by patient at baseline, Day 29 and then every 12 weeks for 12 months. Assessed until 19 Sep 2016 DCO.|Efficacy of Olaparib by Time to First Subsequent Therapy or Death (TFST), To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to first subsequent therapy or death (TFST)., Time elapsed from randomization to first subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.|Efficacy of Olaparib by Time to Second Subsequent Therapy or Death (TSST), To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to second subsequent therapy or death (TSST)., Time elapsed from randomization to second subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.|Efficacy of Olaparib by Time From Randomization to Study Treatment Discontinuation or Death (TDT), To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to study treatment discontinuation or death (TDT)., Time elapsed from randomization to study treatment discontinuation or death. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.|Efficacy in Patients With a Deleterious or Suspected Deleterious Variant in Either of the BRCA Genes by Assessment of PFS., To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (gene sequencing and large rearrangement analysis)., Radiologic scans performed at baseline then every ~12 weeks for the first 72 weeks, then every ~24 weeks thereafter, assessed until disease progression. Assessed until 19 Sep 2016 DCO.|To Determine the Exposure to Olaparib by Pharmacokinetic Analysis, To determine the exposure to olaparib in patients receiving olaparib maintenance monotherapy, Pharmacokinetics sampling to be performed in a subset of patients. Sampling times: Day 1 pre-dose & 1 hour; Day 15 pre-dose & 1 hour; Day 29 pre-dose. Assessed until 19 Sep 2016 DCO.",,AstraZeneca,"European Network of Gynaecological Oncological Trial Groups (ENGOT)|Myriad Genetic Laboratories, Inc.|Merck Sharp & Dohme LLC",FEMALE,"ADULT, OLDER_ADULT",PHASE3,327,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",D0816C00002|2013-001211-75,2013-09-03,2016-09-19,2025-12-31,2013-06-11,2018-02-07,2025-03-25,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Palo Alto Foundation Medical Group, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Gynecologic Cancer Center, Orlando, Florida, United States|North Shore University, Evanston, Illinois, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Johns Hopkins, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|MD Anderson at Cooper Cancer Center, Voorhees, New Jersey, United States|Womens Cancer Care Associates, Albany, New York, United States|Winthrop Gynecologic Oncology Associates, Mineola, New York, United States|OSU JamesCare at Mill Run, Hilliard, Ohio, United States|Henry Joyce Cancer Clinic, Nashville, Tennessee, United States|Aurora St Lukes Medical Center, Milwaukee, Wisconsin, United States|Mercy Hospital for Women, Heidelberg, Australia|The Royal Womens Hospital, Parkville, Australia|Prince of Wales Hospital, Randwick, Australia|U.Z. Gent, Gent, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Centro Diagnóstico Barretos, Barretos, Brazil|Centro Regional Integrado de Oncologia, Fortaleza, Brazil|Hospital Araujo Jorge, Goiânia, Brazil|Hospital de Caridade de Ijuí, Ijuí, Brazil|Centro de Novos Tratamentos Itajai, Itajai, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alagre, Porto Alegre, Brazil|Hospital de Base São José do Rio Preto, São José do Rio Preto, Brazil|Centro de Referencia da Saude da Mulher, São Paulo, Brazil|Instituto do Câncer de São Paulo, São Paulo, Brazil|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Sunnybrook Health Sciences Center, Toronto, Ontario, Canada|CHUM - Hopital Norte-Dame, Montreal, Quebec, Canada|CHUS Site Fleurimont, Sherbrooke, Quebec, Canada|Hotel-Dieu de Quebec, Quebec, Canada|Beijing Cancer Hospital, Beijing, China|The Tumor Hospital affiliated to China Medical Science Insti, Beijing, China|1st Hospital of Jilin university, Changchun, China|Jilin Provincial Cancer Hospital, Changchun, China|Hunan Cancer Hospital, Changsha, China|West China Hospital Affiliated to Sichuan University, Chengdu, China|ChongQing Cancer Hospital, Chongqing, China|Research Site, Guangzhou, 510060, China|Women's Hospital, Zhejaing University School of Medicine, Hangzhou, China|The Tumour Hospital of Harbin Medical University, Harbin, China|Zhejiang Cancer Hospital, Huangzhou, Huangzhou, China|JINAN, Qi Lu Hosp. of SD Univ., Ji Nan, China|Research Site, Shanghai, 200011, China|Shanghai Cancer Hospital of Fudan University, Shanghai, China|The First Affiliated Hospital of Soochow University, Suzhou, China|First affiliated hospital college of XianJiaotong University, Xian, China|Institut Bergonie, Bordeaux, France|CAC François Baclesse, Caen Cedex, France|69LYON, C Bérard, Onco, Lyon Cedex 08, France|Centre Catherine de Sienne, Nantes,, France|Institut Curie Paris Et Saint Cloud, Paris Cedex 5, France|75PARIS, H Tenon, Onco, Paris, France|Hopital Européen Georges Pompidou, Paris, France|69PIERREBE, CH Lyon Sud,, Pierre Benite Cedex, France|92STCLOUD, C Huguenin, Onco, Saint Cloud, France|Institut Claudius Regaud, Toulouse, France|Centre Alexis Vautrin, Vandoeuvre Les Nancy, France|Institut Gustave Roussy, Villejuif Cedex, France|Helios-Kliniken Berlin - Buch, Berlin, Germany|Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany|Klinikum Essen-Mitte,Evang. Huyssens-Stiftung/Knapps gGmbH, Essen, Germany|Johann-Wolfgang Goethe-Universität, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|Klinikum rechts der Isar der Technischen Universität, München, Germany|Onkologie Ravensburg, Ravensburg, Germany|Universitätsklinikum Rostock, Rostock, Germany|Rambam Health Care Campus, Haifa, Israel|Sapir Medical Centre, Kfar Saba, Israel|Tel Hashomer, Ramat Gan, Israel|Istituto Europeo di Oncologia, Milano, Italy|Azienda Ospedaliera Policlinico Di Modena, Modena, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto Irccs, Padova, Italy|Istituto Regina Elena-Polo Oncologico Ifo, Roma, Italy|Policlinico Universitario A. Gemelli, Roma, Italy|Hyogo Cancer Center, Akashi-shi, Japan|National Cancer Center Hospital, Chuo-ku, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Saitama Medical University International Medical Center, Hidaka-shi, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama-shi, Japan|Niigata University Medical and Dental Hospital, Niigata-shi, Japan|Kindai University Hospital, Osakasayama-shi, Japan|Hokkaido University Hospital, Sapporo-shi, Japan|Shizuoka Cancer Center, Sunto-gun, Japan|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|Universitair Medisch Centrum St. Radboud, Nijmegen, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Niepubliczny Zaklad Opieki Zdrowotnej Innowacyjna Medycyna, Grzepnica, Poland|SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|Wojewódzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Poland|Centrum Onkologii Instytut im Marii Sklodowskiej-Curie, Warszawa, Poland|Szpital Specjalistyczny im. Swietej Rodziny SPZOZ, Warszawa, Poland|Chemotherapy Department, Russian Cancer Research Centre, Moscow, Russian Federation|St.Petersburg City Oncology Dispensary, Dept. Gynecology, Saint Petersburg, Russian Federation|Leningrad Regional Oncology Dispensary, St.Petersburg, Russian Federation|Barcelona,H.Clinic i Provincial,Oncología, Barcelona, Spain|Barcelona,H.de la Sta.Creu i S.Pau,Oncología, Barcelona, Spain|Córdoba,H.Reina Sofía,Oncología, Córdoba, Spain|Gerona,H.Josep Trueta,Oncología, Gerona, Spain|Madrid, H.C.S.Carlos,Oncología, Madrid, Spain|Madrid,H.12 de Octubre,Oncología, Madrid, Spain|Hospital Provincial de Navarra, Pamplona, Spain|Valencia, IVO, Oncología, Valencia, Spain|Valencia,H.C.U.Valencia,Oncología, Valencia, Spain|City Hospital Birmingham Cancer Trials Team, Birmingham, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Arden Cancer Centre, Coventry, United Kingdom|Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom|Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Royal Marsden Hospital and Institute of Cancer Research, Sutton, United Kingdom",
